2009-08-28 13:54:19 - Bharatbook.com has launched a new report on "Commercial Insight: Antihormonal Cancer Therapies - Stagnant sales indicative of a mature market" which provides in-depth analysis on antihormonal therapy sales forecasts for brands and generics from 2008 to 2018

Commercial Insight: Antihormonal Cancer Therapies - Stagnant sales indicative of a mature market

Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in

the seven major pharmaceutical markets in 2008. ( www.bharatbook.com/Market-Research-Reports/Commercial-Insight-An .. )

Scope of this research

In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot
Antihormonal therapy sales forecasts for brands and generics from 2008 to 2018
Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
Evaluation of the strategies of leading players in the antihormonals market

Research and analysis highlights

The antihormonals market was worth $6.9 billion in 2008 across the seven major pharmaceutical markets. Its growth within the next decade, at a marginal CAGR of 0.1%, will be predominantly limited by patent expiries of leading brands.
In 2008, Arimidex (anastrozole; AstraZeneca), Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca) were the three leading antihormonal brands in terms of sales. These will remain the top three brands through to 2018, even though Arimidex and Casodex will lose around 40% of their brand value due to generic competition.
In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2008, with an antihormonals portfolio valued at over $3.4 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.

Key reasons to purchase this research

Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2008 to 2018
Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth
Benchmark the antihormonal therapy cancer brands against generics and rest of class and align their 7MM performance with a rest of world snapshot

To know more and to buy a copy of your report feel free to visit : ( www.bharatbook.com/Market-Research-Reports/Commercial-Insight-An .. )

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Blog: bharatbookresearch.blogspot.com